THEME: "Novel solutions to the greatest challenges in pharmaceutical development"
14-15 Nov 2022 
TIME Asma Hotel Albarsha, Dubai, UAE & Online 
UIN Syarif Hidayatullah Jakarta, Indonesia
Title: Treatment outcomes of drug-resistant tuberculosis in Indonesia, 2018-2021
Mita Restinia to apply her accumulated experience in the field of pharmacy practice, pharmacovigilance, clinical pharmacology, and pharmacoepidemiology in infectious diseases mainly tuberculosis. Her research aims to achieve successful treatment, identify and minimize adverse drug reactions and drug interactions, and to summit drug safety in infectious illness treatment. She has GCP certified and authored a book tittled“Guidelines of pharmaceutical care”. In addition, she has a passion for delivering science to both scientific and non-scientific audiences. She decorates these skills by doing science communication at the national and international levels. Besides, her strong experience as a faculty lecturer also tailored her ability to design curriculum, teaching, presentation, and good communication skill. It also helps her to deliver scientific material to the faculty-student as well as become a speaker for pharmacy.
Drug-resistant tuberculosis (DR-TB) poses a threat to public health. One of the biggest obstacles in achieving TB elimination is the rate of successful treatment. Therefore, we aimed to analyze the treatment outcome and the correlation of sociodemographic and clinical parameters with the incidence of poor outcomes of TB treatment among DR-TB patients in Indonesia. This was a retrospective cohort study of adult patients with confirmed DR-TB who were treated from 2018-2021 in one of the public hospitals in Kudus, Indonesia. The association of Predictors for unsuccessful TB treatment (default, failure, and death) was analyzed using Chi-Square. In all, 136 patients were enrolled during the study period, comprising 74(54.4%) males and 62(45.6%) females with a mean age of 49.14 years. Among those patients, 36% were cured and 64% were treated unsuccessfully with 32.4% defaulting, 29.4% dying, and 2.2% failing treatment. All patients with no adherence to their treatment had poor outcomes. Four types of DR-TB were identified from the included patients, i.e, Rifampicin resistant (93.4%), Poly-resistance (3.7%), extensively drug-resistance (2.2%), multidrug-resistance (0.7%). The majority of the patients with poly-resistance, extensive drug resistance, and multidrug resistance did not respond to the therapy. Statistical analysis showed that gender (P=0.042), marital status (P=0,021), adherence to visiting hospitals (P=0.000), and duration of treatment affected significantly the incidence of unsuccessful treatment. This study highlighted that the treatment success rate of drug-resistant TB patients in Kudus, Indonesia was poor. To further improve the treatment outcome, providing special attention, enhanced clinical management, and education should be given to patients with high-risk DR-TB patients.
